Oncology Advances

h rule

Preventing Drug Resistance in Advanced Renal Cell Carcinomas

Genitourinary cancer researchers at Dana-Farber/Brigham and Women’s Cancer Center are investigating novel therapeutics and drug combinations that may circumvent the development of resistance to targeted therapies in patients with metastatic or recurrent renal cell carcinoma.

> Read the full article

h rule

Team Develops Genomic Test to Pinpoint Brain Tumor Diagnoses and Deliver Valuable Information for Prognosis and Clinical Research

Cytogeneticists and pathologists in the Department of Pathology and Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center have developed a whole genome array comparative genomic hybridization test (array CGH) to accurately diagnose various types of brain tumors.

> Read the full article

h rule

The Prostate in 3-D: A Model for Preserving Continence and Sexual Function

Adam S. Kibel, MD, Disease Center Leader, Urology at Dana-Farber/Brigham and Women’s Cancer Center, and colleagues are leading research to determine whether 3-D modeling could improve management of patients with prostate cancer.

> Read the full article

h rule

Novel Neoadjuvant Trial Demonstrates Biomarker Response in Patients with Malignant Pleural Mesothelioma

Experts from Dana-Farber/Brigham and Women’s Cancer Center recently presented preliminary results of an ongoing Phase II investigator-initiated neoadjuvant study of defactinib in patients with surgically-resectable malignant pleural mesothelioma and have modified the trial for subsequently enrolled patients.

> Read the full article

h rule

Dana-Farber/Brigham and Women’s Cancer Center Research on Monoclonal Antibodies Shows Promise in Multiple Myeloma

New monoclonal antibodies for multiple myeloma co-developed by hemato-oncologists at the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women’s Cancer Center could become the next blockbusters in this malignancy. According to results from two recently published clinical trials, the new drugs have impressive efficacy in patients with relapsed and relapsed/refractory disease.

> Read the full article

h rule

Radiation Therapy for Prostate Cancer, Innovative BWH Technique Preserves Rectal Tissue

Dana-Farber/Brigham and Women’s Cancer Center was the first center in Massachusetts and one of the first in the United States to use an innovative technique for preserving rectal tissue while increasing the effectiveness of radiation therapy for treating adenocarcinoma of the prostate.

> Read the full article

h rule

Early-phase Trials at Dana-Farber/Brigham and Women’s Cancer Center Explore Novel Combinations for Ovarian Cancer

Building on recent discoveries at Dana-Farber/Brigham and Women’s Cancer Center using a variety of inhibitor combinations, researchers in the Susan F. Smith Center for Women’s Cancers are leading new early-phase trials for patients with ovarian cancer.

> Read the full article

h rule

Researchers Investigate Ductal Cell Carcinoma In-Situ, Propose Less Aggressive Strategies for Low-risk Lesions

Breast cancer specialists at Dana-Farber/Brigham and Women’s Cancer Center are pioneering efforts to identify subsets of patients with ductal cell carcinoma in-situ (DCIS) who might appropriately avoid aggressive treatment.

> Read the full article

h rule

PD-1 Inhibitor Trials Target Gastrointestinal Cancers, Span Many Cancer Types in Combination Studies

Immunotherapy trials at Dana-Farber/Brigham and Women’s Cancer Center using PD-1 inhibitors have expanded to include studies for several gastrointestinal cancers and combination studies spanning a wide range of cancers.

> Read the full article

h rule

New Study Finds Many Patients Choose Mastectomy, Despite Eligibility for Breast Conserving Therapy

Mehra Golshan, MD, Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology at Brigham and Women’s Hospital and Medical Director of International Oncology Programs at Dana-Farber/Brigham and Women’s Cancer Center, presented findings evaluating the impact of neoadjuvant chemotherapy in Stage II-III triple negative breast cancer on eligibility for breast conserving surgery.

> Read the full article

h rule

New Clinic Studies Innovative Approaches to Prevent the Progression of Blood Cancer in Patients with Precursor Conditions

The new Blood Cancer Prevention of Progression Clinic is designed to enhance the understanding of the progression and clonal evolution of blood cancers in order to provide targeted approaches to prevent the development of blood cancers in patients with precursor conditions.

> Read the full article

h rule

Thyroid Cancer Center Focuses on Targeted Therapy, Tailored Approaches to Evaluation and Treatment

The multidisciplinary team in the new Thyroid Cancer Center is employing novel approaches to the evaluation, diagnosis, treatment, and management of all forms of thyroid cancer, as well as nodular disease.

> Read the full article

h rule

New Immunotherapy Trials Introduce Novel Patient-specific Approaches to Brain Tumor Treatment

Neuro-oncologists in the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center are offering a portfolio of clinical trials in immunotherapy and new targeted therapies for patients with glioblastoma, glioma, and other brain tumors.

> Read the full article

h rule

Immune Checkpoint Inhibitor Therapy Demonstrates High Response Rates

At the American Society for Hematology (ASH) Annual Meeting
in December 2014, Philippe Armand, MD, PhD, a medical oncologist in the Center for Hematologic Malignancies at Dana-Farber/Brigham and Women’s Cancer Center, presented preliminary results from a Phase I trial of nivolumab, a monoclonal antibody directed against PD-1, in patients with relapsed or refractory Hodgkin Lymphoma.

> Read the full article

h rule

National Clinical Trial Using TORS Aims to Decrease Extent of Treatment for Head and Neck Cancer Patients

Specialists in head and neck cancer at Dana-Farber/Brigham and Women’s Cancer Center are participating in a national clinical trial that risk stratifies patients with HPV-positive oropharyngeal squamous cell carcinoma following transoral robotic surgery (TORS) in an effort to reduce postoperative radiation and chemotherapy.

> Read the full article

h rule

Pinpointing Resistance Mutations in Anaplastic Thyroid Cancer

A team of surgeons, medical oncologists, cancer researchers and geneticists at Dana-Farber/Brigham and Women’s Cancer Center is working to improve outcomes for patients with anaplastic thyroid cancer.

> Read the full article

h rule

Dana-Farber/Brigham and Women’s Cancer Center Experts Present Groundbreaking Findings at ASCO

At the 50th Annual Meeting of the American Society of Clinical Oncology, more than 75 investigators from Dana-Farber/Brigham and Women’s Cancer Center presented new research results, including groundbreaking findings that may lead to changes in the standard of care for appropriate patient populations.

> Read the full article

h rule

New Strategies Combat Resistance to EGFR Inhibitors in Lung Cancer Patients

Oncologists in the Lowe Center for Thoracic Oncology at Dana-Farber/Brigham and Women’s Cancer Center are leading new approaches for non-small cell lung cancer patients who develop resistance to current epidermal growth factor receptor inhibitors. Medical oncologists in the Center lead an average of 15 clinical trials at a time and were among the first to discover EGFR mutations in non-small cell lung cancer and demonstrate clinical response to gefitinib and erlotinib in patients with EGFR mutations.

> Read the full article

h rule

T-DM1 Trials Lead to Expanded Options for Patients with HER2-positive Breast Cancer

Medical oncologists in the Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer Center are conducting trials of ado-trastuzumab emtansine (T-DM1) to provide new options for patients with early-stage disease and enhance treatment response in patients with advanced HER2-positive breast cancer.

> Read the full article

h rule

Center for Immuno-Oncology Studies Span Many Cancer Types

Facilitating collaboration in immunotherapy research encompassing a broad range of solid tumors and hematologic malignancies, specialists in the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer are currently offering 12 trials and have six additional studies in development.

> Read the full article

h rule

Esophageal and Gastric Cancer Specialists Develop New Therapeutic Approaches and Assessments for Treatment Response and Prognosis

In the Center for Esophageal and Gastric Cancers, a multidisciplinary team of specialists is developing new therapeutic approaches to improve care for patients with esophageal and gastric cancers.

> Read the full article

h rule

Image-guided Laser Ablation Provides Innovative Treatment Option for Primary and Metastatic Brain Tumors and Radiation Necrosis

Experts in neurosurgery and radiology at Dana-Farber/Brigham and Women’s Cancer Center are delivering interstitial laser ablation for the treatment of a range of intracranial lesions using a novel combination of imaging and ablative techniques.

> Read the full article

h rule

National Trial Evaluates Novel Approach for Younger Adults with Newly Diagnosed Multiple Myelomas

Hemato-oncologists in the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women’s Cancer Center are leading a national clinical trial for younger adult patients newly diagnosed with multiple myeloma.

> Read the full article

h rule

Early Vaccine Therapy Demonstrates Promise in Longer-term Control of Chronic Lymphocytic Leukemia

Results from a clinical trial led by investigators at Dana-Farber/Brigham and Women’s Cancer Center suggest that vaccination may be effective in advancing long-term leukemia control following reduced intensity conditioning regimens in stem cell transplantation.

> Read the full article

h rule

Profile® Team Transitions to Next-generation Sequencing and Launches New Investigations

Researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital have transitioned Profile®, one of the nation’s most comprehensive personalized medicine initiatives in cancer, to next-generation sequencing and have launched new clinical investigations supported by Profile data.

> Read the full article

h rule

Novel Therapies and Innovative Neurosurgical Procedures for Patients
with Malignant Brain Tumors

Specialists at Dana-Farber/Brigham and Women’s Cancer Center are offering a range of early-phase studies evaluating novel therapies and innovative, image-guided neurosurgical approaches for malignant brain tumors.

> Read the full article

h rule

Managing and Preventing Thrombosis in Oncology Patients

One of few dedicated services of its kind for oncology patients, the Anticoagulation Management Service at Dana-Farber/Brigham and Women’s Cancer Center provides expert care and anticoagulation management for patients undergoing cancer treatment.

> Read the full article

h rule

NCCN Conference Presentations Inform National Cancer Care Guidelines

Oncology experts from Dana-Farber/Brigham and Women’s Cancer Center presented new guidelines for survivorship care and the latest advances in treatment for prostate, thyroid, and kidney cancers and multiple myeloma.

> Read the full article

h rule

Robotic Technique Benefits Patients with Pancreatic Cysts and Tumors

Robotic distal pancreatectomy, performed by specialists in the Pancreatic Tumor Program at Dana-Farber/Brigham and Women’s Cancer Center, results in less blood loss and faster recovery compared with open pancreatectomy, as well as greater freedom of movement compared with a traditional laparoscopic approach.

> Read the full article

h rule

Pioneering New Discoveries in Genetic Risk Profiling in Prostate Cancer

At Dana-Farber/Brigham and Women’s Cancer Center, groundbreaking research studies in genetic risk profiling in prostate cancer span somatic and germline mutations and strive to identify new targeted therapies for prostate cancer, distinguish aggressive prostate cancer from indolent forms of the disease, and predict who is at higher risk for prostate cancer.

> Read the full article

h rule

Advanced Multimodality Imaging Enables New Interventions

Specialists at Dana-Farber/Brigham and Women’s Cancer Center are collaborating to employ new image-guided techniques in the Advanced Multimodality Image Guided Operating (AMIGO) suite at Brigham and Women’s Hospital (BWH) in order to advance treatment for many forms of cancer.

> Read the full article

h rule

Defining Predictors of Success to Tailor Therapy for Patients with Leukemia

Hematologic oncologists at Dana-Farber/Brigham and Women’s Cancer Center have developed a novel predictive biomarker to determine which patients who initially respond to chemotherapy for leukemia will continue in remission and which patients are likely to relapse and benefit from bone marrow transplantation.

> Read the full article

h rule

Novel Tests Determine Prognosis and Confirm Diagnosis in Mesothelioma

Gene expression ratio tests, developed and validated at Dana-Farber/Brigham and Women’s Cancer Center, confirm differential diagnosis and predict survival in patients undergoing surgical treatment for mesothelioma.

> Read the full article

h rule

New Melanoma Clinical Trials Build on Recent Successes

Medical oncologists in the Center for Melanoma Oncology are pioneering new treatment approaches, including new trials of combination and adjuvant therapies, for all forms of melanoma.

> Read the full article

h rule

Advances in Kidney Cancer Treatment and Onco-Nephrology

Specialists at Dana-Farber/Brigham and Women’s Cancer Center are offering numerous innovative treatment approaches for patients with kidney cancer and kidney complications from cancer treatment.

> Read the full article

h rule

Dana-Farber, Brigham and Women’s launch Profile, one of the most comprehensive research initiatives in personalized cancer medicine

Committed to speeding the development of cancer treatments that target the genetic weaknesses in each patient’s tumor, Dana-Farber Cancer Institute and Brigham and Women’s Hospital launched Profile® a major effort to scan tumor tissue from adult cancer patients for hundreds of gene mutations linked to cancer.

> Read the full article

h rule

Older Adults with Leukemia: Answers to five common questions

Dana-Farber/Brigham and Women's Cancer Center has established the Older Adult Leukemia Program, where leukemia patients who are 65 years-of-age or older are evaluated and treated by members of the leukemia team and a geriatric oncologist.

> Read the full article

h rule

Dedicated, Specialized Treatment for Triple-negative Breast Cancer

The Breast Oncology Center has a team of five dedicated breast pathologists who provide expert consultation for difficult to manage breast cancer cases. In addition, research programs at the Center include efforts to better characterize triple-negative breast cancer, identify biomarkers, and develop targeted drugs.

> Read the full article

h rule

Minimally Invasive Thoracic Surgery Delivers Significant Patient Benefits

Thoracic Oncology Center surgeons perform robotic surgery for thoracic lesions, enabling a broader range of patients to undergo minimally invasive surgical treatment including robotic lobectomy, robotic mediastinal tumor resection, and other approaches.

> Read article and watch Jon Wee, MD, perform a robotic lobectomy

h rule

Pregnancy and Breast Cancer: Making it Through

The Program for Young Women with Breast Cancer assists women in their early 40s and younger before, during, and after cancer treatment and works collaboratively with BWH reproductive endocrinology and high-risk pregnancy programs.

> Read the full article

h rule

Organ Preservation Techniques Improve Quality of Life for Patients

Head and Neck Oncology Center specialists are employing advanced multidisciplinary approaches to achieve the best functional outcome for each patient, including a combination of radiation and medical therapies, as well as surgery when necessary.

> Read the full article

h rule

Advanced Multimodality Image-Guided Operating Suite Enhances Neurosurgical Procedures and Enables New Interventions

The nation's first integrated operating suite to offer immediate intra-procedural access to an extensive range of advanced imaging modalities, the new AMIGO Suite is divided into three interconnected procedure rooms housing real-time anatomic, functional, and molecular imaging, including 3T MRI, PET/CT, fluoroscopy, and ultrasound.

> Read the full article

h rule

Cutting-edge Medical, Surgical, and Radiation Approaches and Genetic Findings in Colorectal Cancer

Clinical trials combining multiple agents, advanced radiation therapies, minimally invasive surgical techniques, and genetic testing and discoveries are improving earlier detection and outcomes for patients with colorectal cancer.

> Read the full article

h rule

New Approaches in Clinical Trials for Gynecologic Cancers 

Spanning multiple disciplines, including medical oncology, radiation oncology, and gynecologic oncology, clinical trials for gynecologic cancers are offering new treatment options for patients.

> Read the full article

 

Share this newsletter

Clinical Trials

Review available trials
> Research advances
 

 

Harvard Medical School© 2016 Dana-Farber/Brigham and Women's Cancer Center, Boston, MA
Phone: (877) DFCI-BWH / (877) 332-4294
www.dfbwcc.org